Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis

Min Jung Kang, Myung Sin Kim, Eun Hwa Choi, Kyoung Eun Lee, You Kyoung Kim, Hee Jung Choi

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Inhibitors of tumor necrosis factor-alpha (TNF-α) have been approved for treating rheumatoid arthritis. As one of the biological response modifiers, etanercept has also been used in the treatment of psoriatic arthritis and inflammatory bowel disease. While etanercept is effective, certain infectious complications, such as tuberculosis, fungus, and cytomegalovirus, have been reported. We report the first Korean case of adenoviral pneumonia in a 55-year-old female who developed disseminated adenoviral infection following etanercept treatment, which resolved after anti-TNF-α discontinuation.

Original languageEnglish
Pages (from-to)63-66
Number of pages4
JournalKorean Journal of Internal Medicine
Issue number1
StatePublished - 2007


  • Adenovirus infections
  • Human
  • Pneumonia
  • TNFR-Fc fusion protein
  • Tumor necrosis factor-alpha


Dive into the research topics of 'Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this